Phasebio Pharmaceuticals Stock Probability Of Bankruptcy
PhaseBio Pharmaceuticals' odds of distress is above 80% at this time. It has very high probability of going through financial hardship in the upcoming years. Probability of distress prediction helps decision makers evaluate PhaseBio Pharmaceuticals' chance of financial distress in relation to its going-concern outlook and evaluation. All items used in analyzing the odds of distress are taken from the PhaseBio balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
PhaseBio |
PhaseBio Pharmaceuticals Company probability of distress Analysis
PhaseBio Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current PhaseBio Pharmaceuticals Probability Of Bankruptcy | Over 100% |
Most of PhaseBio Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PhaseBio Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of PhaseBio Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting PhaseBio Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of PhaseBio Pharmaceuticals financial health.
Please note, there is a significant difference between PhaseBio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if PhaseBio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PhaseBio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, PhaseBio Pharmaceuticals has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the Healthcare sector and 82.35% higher than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
PhaseBio Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PhaseBio Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of PhaseBio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing PhaseBio Pharmaceuticals by comparing valuation metrics of similar companies.PhaseBio Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers.
PhaseBio Fundamentals
| Return On Asset | -1.06 | |||
| Operating Margin | (127.39) % | |||
| Current Valuation | (1.26 M) | |||
| Shares Outstanding | 49.86 M | |||
| Shares Owned By Insiders | 6.72 % | |||
| Shares Owned By Institutions | 25.02 % | |||
| Number Of Shares Shorted | 2.07 M | |||
| Price To Book | 26.18 X | |||
| Price To Sales | 1.58 X | |||
| Revenue | 10.83 M | |||
| Gross Profit | (91.28 M) | |||
| EBITDA | (126.73 M) | |||
| Net Income | (131.07 M) | |||
| Cash And Equivalents | 7.8 M | |||
| Cash Per Share | 0.16 X | |||
| Total Debt | 1.36 M | |||
| Current Ratio | 0.47 X | |||
| Book Value Per Share | (2.35) X | |||
| Cash Flow From Operations | (47.42 M) | |||
| Short Ratio | 1.89 X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 60 | |||
| Beta | 2.52 | |||
| Market Capitalization | 1.05 M | |||
| Total Asset | 60.54 M | |||
| Z Score | -6.6 | |||
| Net Asset | 60.54 M |
Pair Trading with PhaseBio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PhaseBio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PhaseBio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Intercontinental could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Intercontinental when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Intercontinental - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Intercontinental Exchange to buy it.
The correlation of Intercontinental is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Intercontinental moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Intercontinental Exchange moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Intercontinental can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in PhaseBio Pink Sheet
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stocks Directory Find actively traded stocks across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |